logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Interleukin-23 Antagonist class drugs

    FiltersReset Filters
    9 results

    • ilumya

      (tildrakizumab-asmn)
      Sun Pharmaceutical Industries, Inc.
      Usage: ILUMYA® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who qualify for systemic therapy or phototherapy.

    • omvoh

      (mirikizumab-mrkz)
      Eli Lilly and Company
      Usage: OMVOH is indicated for the treatment of moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease in adults.

    • pyzchiva

      (ustekinumab-ttwe)
      SANDOZ INC
      Usage: PYZCHIVA is indicated for adults and pediatric patients aged 6 and older with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis. It is designed for patients suitable for phototherapy or systemic therapy.

    • selarsdi

      (ustekinumab-aekn)
      Teva Pharmaceuticals USA, Inc.
      Usage: SELARSDI™ is indicated for treating moderate to severe plaque psoriasis in patients 6 years and older, active psoriatic arthritis in the same age group, and moderately to severely active Crohn’s disease and ulcerative colitis in adults.

    • skyrizi

      (Risankizumab-rzaa)
      AbbVie Inc.
      Usage: SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis in adults.

    • stelara

      (ustekinumab)
      Janssen Biotech, Inc.
      Usage: STELARA® is indicated for treating moderate to severe plaque psoriasis in patients 6 years and older, active psoriatic arthritis in patients 6 and older, and moderately to severely active Crohn's disease and ulcerative colitis in adult patients.

    • tremfya

      (Guselkumab)
      Janssen Biotech, Inc.
      Usage: TREMFYA is indicated for adult patients with moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active ulcerative colitis, specifically those who are candidates for systemic therapy or phototherapy.

    • ustekinumab-ttwe

      (ustekinumab-ttwe)
      Quallent Pharmaceuticals Health LLC
      Usage: Ustekinumab-ttwe is indicated for the treatment of moderate to severe plaque psoriasis in patients aged 6 and older, active psoriatic arthritis in patients 6 and older, and moderately to severely active Crohn's disease and ulcerative colitis in adults.

    • yesintek

      (ustekinumab)
      Biocon Biologics Inc.
      Usage: YESINTEK is indicated for treating moderate to severe plaque psoriasis in patients aged 6 and older, active psoriatic arthritis in patients 6 and older, and moderately to severely active Crohn's disease and ulcerative colitis in adults.